Maxim Pharma (MAXM) - exzellentes Management - 500 Beiträge pro Seite

[IWA Japan]

[IWA Japan]

MAXM scheint angesichts der Meldungen der vergangenen Wochen wirklich über ein exzellentes Management zu verfügen.

Aber fange ich lieber erst mal mit einer anderen Meldung an betreffend MAXM Hauptprodukt Mamamine:

Wednesday July 19, 3:06 am Eastern Time
Company Press Release
Maxim Pharmaceuticals Submits New Drug Application for Maxamine With FDA
SAN DIEGO--(BW HealthWire)--July 19, 2000--Maxim Pharmaceuticals (Nasdaq NM:MAXM - news; SSE:MAXM) announced that it has submitted a New Drug Application with the U.S. Food and Drug Administration seeking approval to market its proprietary histamine dihydrochloride (Maxamine) drug in the United States as an adjuvant to interleukin-2 (IL-2) for the treatment of stage-IV malignant melanoma.
Maxamine was granted orphan drug status by the FDA in February as an adjunct to cytokine therapy. Orphan drug status provides for U.S. marketing exclusivity for seven years upon marketing approval by the administration.


Das war wie die Unternemhensführung selbst sagte, der bislang wichtigste Meilewnstein in der Unternehmensgeschichte. Eienr erfolgreichen VErmarktung stewht jetzt wohl nichts mehr im Wege...

[IWA Japan]

der ANlass meines Threads ist aberzunächst mal die erfolgreiche ÜBernahmen der privaten BT Firma Cytova und den daraus resultierenden Erfolgen:

Maxim Pharmaceuticals (Nasdaq:MAXM - news; SSE:MAXM) announced that it has licensed its CV2105 series of anti-cancer compounds to BioChem Pharma Inc.... The agreement requires that BioChem make licensing, research and milestone payments to Maxim totaling up to U.S. $55 million, as well as pay a royalty on product sales resulting from this collaboration....CV2105 is one of 25 anti-cancer product candidates identified to date by Maxim`s wholly owned subsidiary, Cytovia, Inc, through its proprietary high-throughput screening technology

tja, wenn man bedenkt, dass MAXM selbst nur 80 Mio $ für Cytova hinlegte, zeigt sich doch, wie wertvoll diese ÜBernamhne war. Es dürfte wohl wahrschewinlich sein, dass noch weitere von den insg. Präparaten auslizensisiert werden, was auch kurzfristig schon für weitere Einnamhne sorgt.


und der nächste Deal mit Cytova

GPC Biotech forms alliance with Cytovia
FRANKFURT, July 25 (Reuters) - German biotechnology firm GPC Biotech AG said on Tuesday it had formed a strategic alliance with Cytovia Inc. of the United States, a unit of Maxim Pharmaceuticals Inc. (NasdaqNM:MAXM - news).

GPC said that under the agreement Cytovia would license to GPC certain mammalian cell-based assay technologies which GPC would use in its drug discovery programmes and its pharmaceutical partnerships.


Dieser Deal ist vielleicht nicht so lukrativ wie obiger, aber dennoch ein weitere Schritt vom Managment, die Postion von MAXM weiter zu stärken

[IWA Japan]

schon von diesen Entwicklungen sind anderen überzeugt

wie http://www.smallcapsonline.com./main.php3?ticker=maxm&page=m…SmallCaps Online LLC announced today that it has issued an update on Maxim Pharmaceuticals Inc. (NASDAQ:MAXM - news) reiterating its BUY recommendation on the basis of recent business developments. The full text of this report can be accessed at SmallCaps Online`s web site

[IWA Japan]

erst letzten Donnerstag überraschte das Managment die Investoren mit einem sehr wichtigen Deal:

Maxim Pharmaceuticals and Hoffmann -- La Roche Enter Into Significant Development Collaboration
Maxim and Roche Expect Collaboration to Lead to Important Advances in the Treatment of Cancer and Hepatitis C
SAN DIEGO--(BW HealthWire)--Aug. 10, 2000-- Maxim Pharmaceuticals (Nasdaq:MAXM - news; SSE:MAXM) announced that it has entered into a comprehensive development collaboration with F. Hoffmann -- La Roche Ltd, Switzerland and its U.S. branch Hoffmann -- La Roche Inc. for the development of Maxim`s lead drug Maxamine® (histamine dihydrochloride) in combination with the investigational compound Pegasys®, Roche`s pegylated interferon-alpha agent.

Both parties expect that the combination of Maxamine and Pegasys will lead to important advances in the treatment of cancer and hepatitis C.

``Roche clearly represents a great development partner for Maxim due to the success they have had with the clinical development of Pegasys, and the fact that they share our commitment to advancing the treatment of hepatitis C and cancer,`` said Larry G. Stambaugh, Maxim`s chairman and chief executive officer. ``This collaboration not only produces a substantial strategic and economic benefit to us, it allows us to accelerate and expand the clinical development of Maxamine.``
``We are excited about the potential contribution that the combination of Maxamine and Pegasys may make to the treatment of hepatitis C and the targeted cancers,`` said Simon Pedder, Ph.D., Pharmaceutical Business Director for Pegasys. ``Hepatitis C in particular is a substantial unmet need. Our hope is that the addition of Maxamine to Pegasys, an agent that has produced promising clinical data in hepatitis C as a monotherapy, will result in a combination therapy that represents a further improvement in patient care. In addition, the data from the Phase III trial of Maxamine in advanced malignant melanoma encouraged us to move aggressively forward with the development of the Pegasys/Maxamine combination treatment in cancer.``

Under the agreement, Maxim and Roche will undertake clinical trials and other activities designed to seek regulatory approval of the combination of Maxamine and Pegasys for the treatment of hepatitis C and certain cancers. Specifically, the collaboration program will include two Phase III trials of the Maxamine and Pegasys combination for the treatment of hepatitis C, one Phase III trial of Maxamine and Pegasys for the treatment of advanced-stage renal cell carcinoma, and an additional Phase III trial in another cancer to be selected by the two companies.

Roche will perform the management, monitoring and data management of the trials at its own cost and Roche and Maxim will share equally the third party costs of the trials. Each company will retain marketing responsibilities and revenues for their respective drugs, although under the collaboration agreement they will cooperate in the training of their respective sales forces.

The U.S. Phase III trial of Maxamine for the treatment of malignant melanoma was completed in March 2000 and the related New Drug Application was filed by Maxim with the U.S. Food and Drug Administration in July 2000. In addition, interim 24-week results from a Phase II dose-ranging hepatitis C study showed that the combination of the optimal dosing regimen of Maxamine and interferon-alpha achieved a complete viral response in 69 percent of all patients, compared to the 29 percent or less response that is commonly observed in patients treated with interferon-alpha alone.

Maxamine Mode of Action

Research suggests that a universal mechanism in the human body suppresses the capacity of the immune system to detect and destroy tumor cells or virally infected cells in patients with cancer and chronic infectious diseases. Maxamine is designed to reverse this immune suppression, thereby enhancing the effectiveness of immunotherapy, a class of therapies that employ the body`s immune system to fight these diseases. Maxamine protects critical immune cells and is administered in combination with stimulators of these same immune cells (cytokines such as interferon-alpha and IL-2). More than 1,200 patients have been treated in the Maxim`s completed and ongoing clinical trials.

In addition to the U.S. Phase III trial for the treatment of malignant melanoma completed in March 2000, Maxamine is currently being tested in two additional Phase III cancer clinical trials in 12 countries for malignant melanoma and acute myelogenous leukemia. Phase II trials of Maxamine are also underway for the treatment of hepatitis C and advanced renal cell carcinoma. Maxamine is an investigational drug and safety and efficacy have not been established at this time. However, clinical trial results to date suggest that Maxamine Therapy, the administration of Maxamine in combination with cytokines, is a safe, at-home treatment that may improve patient survival.

[IWA Japan]

aktueller Marktwert: $ 1,162,724,063

und die logische Konsequenz
Princeton, New Jersey, Aug. 10 (Bloomberg Data) -- Maxim Pharmaceuticals Inc. (MAXM US) was reiterated ``strong buy`` by analyst Fariba F Ghodsian at Roth Capital Partners. The price target is $95.

[IWA Japan]

In meinen Augen hat sich durch die oben aufgezeigte Entwicklung der letzten Wochen sowohl die posaitive fundamentale Lage und die Unerbewertung, die MAXM am Markt erfährt nochmals vergrößert, so dass man auf Sicht von mehreren Monaten mit einem INvestment wohl absolut nix flasch machen sollte


IWA Japan. der sich wohl bald auch MAXM zulegt

[IWA Japan]

und? Keine Meinung

[IWA Japan]

und? Keine Meinung

[scriabin]

Hallole!
Wasn das für Zeugs, das Maxa..Dings??
Isn das n Protein, n monoklonaler Antikörper, oder was??
Ich bin ja nur ein Ahnungsloser Medizinstudent, aber im allgemeinen
sind diese High-Tech-Medikamente so A....teuer, daß Sie in Deutschland fast nicht eingesetzt werden.
Abgesehen davon: Krebs läßt sich ganz sicher nicht durch eine kleine Immunmodulation heilen. Steht in jedem neueren Patho-buch.
Alles Biotech Hype.

[bagga]

Unten kurz der Mechanismus der Wirkung von Maxamine (Histamindihydrochlorid). Auch als kleiner ahnungsloser Medizinstudent
solltest Du wissen,das die Patho-bücher, wirklich nicht immer auf dem neuesten Stand sind, die Verlage verlangen in der Regel,
dass nur etablierte zugelassene Therapiekonzepte in Lehrbücher erscheinen dürfen, das ist also wirklich kein Argument, was Histamin ist, solltest Du als Medizinstudent doch wohl wissen, von direkter Heilung ist ja auch gar nicht die Rede, das das Zeugs wirkt, hat mich auch sehr überrascht, aber wenn man damit gut Geld verdienen kann, was solls.


Research suggests that a universal mechanism in the human body suppresses the capacity of the immune system to detect and
destroy tumor cells or virally infected cells in patients with cancer and chronic infectious diseases. Maxamine is designed to
reverse this immune suppression, thereby enhancing the effectiveness of immunotherapy, a class of therapies that employ the
body`s immune system to fight these diseases. Maxamine protects critical immune cells and is administered in combination with
stimulators of these same immune cells (cytokines such as interferon-alpha and IL-2). More than 1,200 patients have been
treated in the Maxim`s completed and ongoing clinical trials.

In addition to the U.S. Phase III trial for the treatment of malignant melanoma completed in March 2000, Maxamine is currently
being tested in two additional Phase III cancer clinical trials in 12 countries for malignant melanoma and acute myelogenous
leukemia. Phase II trials of Maxamine are also underway for the treatment of hepatitis C and advanced renal cell carcinoma.
Maxamine is an investigational drug and safety and efficacy have not been established at this time. However, clinical trial results
to date suggest that Maxamine Therapy, the administration of Maxamine in combination with cytokines, is a safe, at-home
treatment that may improve patient survival.

[RCZ]

@IWA JAPAN

warum kaufst du die Firmen die du gut findest nicht

[IWA Japan]

@RCZ: es gibt genug gute Firmen, stand schon unmittelbar vor dem Kauf, habe es aber dann doch abgeblasen ..


naja, werde mir sie wohl aber demnächst zulegen :


b]P.S: nutzt du nicht das BOard Msail systemm von W


logg dich mal ein

[IWA Japan]

[IWA Japan]

CNBC pick of the week 12 month price target 95




IWA

[IWA Japan]

und ein weitere Grund zum Kauf von MAxim Pharma

New enzyme blocker could save cells in heart, brain


Updated 2:24 PM ET August 23, 2000
By Todd Zwillich
WASHINGTON (Reuters Health) - Physicians may soon have a way to protect the heart and brain from damage that occurs after a heart attack or stroke, according to results presented here at the American Chemical Society meeting.

A reduction in blood during a heart attack or stroke--often due to a clot--can damage cells by reducing their oxygen supply, a condition known as ischemia. Even after the blood supply is restored, many cells undergo a natural cell suicide program and end up dying.

Researchers announced this week that they are ready to move into human trials with a new compound that appears to inhibit a key enzyme in laboratory animals with induced ischemia. If successful, the approach could, for the first time, provide a way to prevent tissue damage following stroke or heart attack.

"We have thrombolytics to break clots. But right now there is nothing to protect (ischemic) cells from dying," Dr. Sui Xiong Cai, told Reuters Health at the meeting.

Cai and his research team from a small San Diego-based company called Maxim Pharmaceuticals, developed a compound with the ability to inhibit an enzyme known as PARP. The enzyme promotes the suicide program that occurs in cells following ischemia.

The researchers pretreated rats with the compound, which is called CV1013. They then blocked an artery that normally supplies blood to the brain, and treated the animals with CV1013 again after the blood supply was restored.

In the end, pretreated animals had 45% less brain damage than rats that received placebo (inactive) injections, Cai reported.

Baltimore-based Guilford Pharmaceuticals is also developing a PARP inhibitor, this one called GPI6150. In their trials, rats that were given the compound before and after ischemia had 80% less damage to the brain than rats treated with inactive injections. Another phase of the study showed a 40% reduction in the size of the damaged area of the heart in treated rats after an ischemic event.

"We plan to move into phase I trials in humans by the end of the year," Guilford researcher Dr. Jai-He Li said in an interview with Reuters Health. Phase I trials are conducted to make sure a compound is safe for use in humans and are performed before more extensive studies are done to determine if a treatment is effective.

[IWA Japan]

was mich an MAXM am meisten Freud. ist , dass sich keienr für die interssiert

Fazit: MAXM ist eine schlummernde Perle